Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZRNASDAQ:NTECNASDAQ:RANINASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZRKezar Life Sciences$4.59-4.2%$4.25$3.62▼$9.18$33.54M0.5856,188 shs36,941 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsRANIRani Therapeutics$0.53-6.3%$0.85$0.46▼$4.45$30.20M0.25815,186 shs303,281 shsSCYXSCYNEXIS$0.81-1.8%$0.90$0.72▼$2.29$31.51M1.65162,366 shs99,492 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZRKezar Life Sciences-4.18%+4.32%+11.14%-21.81%-35.34%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%RANIRani Therapeutics-6.28%-6.20%-5.66%-65.21%-86.87%SCYXSCYNEXIS-1.76%-12.04%-15.00%-13.36%-62.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKZRKezar Life Sciences4.5626 of 5 stars3.25.00.04.63.32.50.6NTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/ARANIRani Therapeutics2.1197 of 5 stars3.51.00.00.02.71.70.6SCYXSCYNEXIS0.8437 of 5 stars0.02.00.00.04.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZRKezar Life Sciences 2.33Hold$39.50760.57% UpsideNTECIntec Pharma 0.00N/AN/AN/ARANIRani Therapeutics 3.00Buy$7.331,296.03% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTEC, SCYX, KZR, and RANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.004/3/2025RANIRani TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZRKezar Life Sciences$7M4.79N/AN/A$25.80 per share0.18NTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ARANIRani Therapeutics$1.20M25.16N/AN/A$0.51 per share1.03SCYXSCYNEXIS$2.63M11.98$1.39 per share0.58$1.96 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZRKezar Life Sciences-$101.87M-$10.82N/AN/AN/AN/A-54.95%-46.11%8/12/2025 (Estimated)NTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ARANIRani Therapeutics-$33.97M-$0.99N/AN/AN/AN/A-219.64%-56.71%8/5/2025 (Estimated)SCYXSCYNEXIS$67.04M-$0.56N/A16.15N/A-425.41%-66.21%-38.84%8/6/2025 (Estimated)Latest NTEC, SCYX, KZR, and RANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 million3/31/2025Q4 2024RANIRani Therapeutics-$0.24-$0.27-$0.03-$0.27N/A$1.03 million3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKZRKezar Life SciencesN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZRKezar Life Sciences0.057.657.65NTECIntec PharmaN/A2.342.34RANIRani Therapeutics2.341.601.60SCYXSCYNEXISN/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZRKezar Life Sciences67.90%NTECIntec Pharma22.37%RANIRani Therapeutics30.19%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipKZRKezar Life Sciences10.40%NTECIntec Pharma3.30%RANIRani Therapeutics50.42%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZRKezar Life Sciences607.31 million6.62 millionNot OptionableNTECIntec Pharma40898,000N/AOptionableRANIRani Therapeutics11057.48 million26.75 millionOptionableSCYXSCYNEXIS6039.02 million36.87 millionOptionableNTEC, SCYX, KZR, and RANI HeadlinesRecent News About These CompaniesReviewing Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX)June 9, 2025 | americanbankingnews.comSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30, 2025 | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 29, 2025 | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28, 2025 | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comSCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study RestartMarch 12, 2025 | quiverquant.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 10, 2024 | globenewswire.comFederated Hermes, Inc. Expands Stake in SCYNEXIS IncOctober 7, 2024 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024October 3, 2024 | globenewswire.comSCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Acquires 20,000 SharesSeptember 17, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingMercadoLibre Is Soaring—Should You Wait for a Better Entry?By Ryan Hasson | May 26, 2025View MercadoLibre Is Soaring—Should You Wait for a Better Entry?Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later? By Jeffrey Neal Johnson | June 6, 2025View Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later? NTEC, SCYX, KZR, and RANI Company DescriptionsKezar Life Sciences NASDAQ:KZR$4.59 -0.20 (-4.18%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.71 +0.12 (+2.61%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Intec Pharma NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.Rani Therapeutics NASDAQ:RANI$0.53 -0.04 (-6.28%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.53 +0.00 (+0.51%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.SCYNEXIS NASDAQ:SCYX$0.82 -0.01 (-0.73%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
